Coeptis Therapeutics Holdings Inc COEP

NAS: COEP | ISIN: US19207A1088 27/06/2025

7,780 USD (-3,11%)

(-3,11%) 27/06/2025

Grafiek Coeptis Therapeutics Holdings Inc

Grafiek Coeptis Therapeutics Holdings Inc

1 dag1d -3,11%
1 week1w 1,70%
1 maand1m -16,34%
3 maanden3m -17,85%
6 maanden6m 31,64%
1 jaar1j 2.641,37%
5 jaar5j 3.790,00%

Coeptis Therapeutics Holdings Inc in het nieuws

Toon enkel gratis nieuws

5 september 2024 · Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders · Persbericht

20 juni 2024 · Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering · Persbericht

30 mei 2024 · Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting · Persbericht

8 mei 2024 · Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024 · Persbericht

2 mei 2024 · Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting · Persbericht

2 april 2024 · Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award · Persbericht

26 februari 2024 · Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK · Persbericht

7 februari 2024 · Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections · Persbericht

4 januari 2024 · Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024 · Persbericht

4 december 2023 · Coeptis Therapeutics to Present at the Emerging Growth Conference · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe